Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma

[1]  F. Chen,et al.  Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review , 2022, Frontiers in Oncology.

[2]  Li Liu,et al.  Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World , 2022, Frontiers in Oncology.

[3]  Jingfeng Liu,et al.  The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review , 2022, Frontiers in Immunology.

[4]  Kang Wang,et al.  Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

[5]  Liyong Pu,et al.  Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial , 2022, Journal for ImmunoTherapy of Cancer.

[6]  Yi‐Hsiang Huang,et al.  Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma , 2022, Cancer Immunology, Immunotherapy.

[7]  Liteng Lin,et al.  Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study , 2022, Frontiers in Immunology.

[8]  Kongming Wu,et al.  Combination strategies with PD-1/PD-L1 blockade: current advances and future directions , 2022, Molecular cancer.

[9]  M. Soulen,et al.  Transarterial Embolization Modulates the Immune Response within Target and Nontarget Hepatocellular Carcinomas in a Rat Model. , 2022, Radiology.

[10]  Wendong Li,et al.  A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma , 2022, Technology in cancer research & treatment.

[11]  Changwen Bo,et al.  nEffect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma , 2021, Clinics and Research in Hepatology and Gastroenterology.

[12]  B. Garicochea,et al.  Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma , 2021, JAMA network open.

[13]  V. Mazzaferro,et al.  Immunotherapies for hepatocellular carcinoma , 2021, Nature Reviews Clinical Oncology.

[14]  S. Raman,et al.  Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  Z. Fu,et al.  Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study , 2021, Hepatology International.

[16]  B. Sangro,et al.  Advances in immunotherapy for hepatocellular carcinoma , 2021, Nature Reviews Gastroenterology & Hepatology.

[17]  A. Griffioen,et al.  Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes , 2021, Nature Reviews Clinical Oncology.

[18]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[19]  R. Lencioni,et al.  Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma , 2021, Nature Reviews Gastroenterology & Hepatology.

[20]  T. Kawaguchi,et al.  Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study , 2021, Cancers.

[21]  Yun Wang,et al.  The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[22]  M. Kudo,et al.  Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib , 2020, JAMA oncology.

[23]  M. Kudo,et al.  A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements , 2020, Liver Cancer.

[24]  W. Huang,et al.  Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients , 2020, Annals of translational medicine.

[25]  M. Kudo,et al.  Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. , 2020, Journal of hepatology.

[26]  R. Lencioni,et al.  mRECIST for HCC: Performance and novel refinements. , 2020, Journal of hepatology.

[27]  M. Kudo,et al.  Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial , 2019, Gut.

[28]  J. Trebicka,et al.  EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. , 2018, Journal of hepatology.

[29]  J. Llovet,et al.  Molecular therapies and precision medicine for hepatocellular carcinoma , 2018, Nature Reviews Clinical Oncology.

[30]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[31]  Yuji Yamamoto,et al.  Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models , 2018, Cancer medicine.

[32]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[33]  J. Prieto,et al.  A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. , 2013, Journal of hepatology.

[34]  Y. Kim,et al.  Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. , 2011, Radiology.

[35]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.